Published in J Clin Oncol on June 01, 1996
Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers | NCT00973882
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol (2011) 2.57
A history of prostate cancer treatment. Nat Rev Cancer (2002) 2.46
Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res (2005) 2.44
Expanding treatment options for metastatic prostate cancer. N Engl J Med (2011) 2.39
Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes (2009) 2.05
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol (2011) 1.94
Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J (2010) 1.78
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol (2013) 1.76
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol (2014) 1.70
Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets (2009) 1.66
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer (2010) 1.57
The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55
Patient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision making. Eur Urol (2013) 1.54
Breast and prostate cancer: more similar than different. Nat Rev Cancer (2010) 1.48
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer (2003) 1.46
New developments in the medical management of prostate cancer. Mayo Clin Proc (2010) 1.41
An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res (2009) 1.36
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer (2007) 1.33
Health-related quality of life and cancer clinical trials. Ther Adv Med Oncol (2011) 1.30
Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol (2008) 1.26
Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle (2008) 1.25
Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. CMAJ (1998) 1.20
Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J (2013) 1.19
Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer (1999) 1.18
Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol (2013) 1.17
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. Br J Cancer (2011) 1.17
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther (2011) 1.14
Current management of castrate-resistant prostate cancer. Curr Oncol (2010) 1.14
The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol (2007) 1.13
Prostate cancer: 9. Treatment of advanced disease. CMAJ (1999) 1.10
One hundred thirteen men with hormone-refractory prostate cancer died today. J Clin Oncol (1996) 1.10
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2011) 1.08
Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br J Cancer (2005) 1.07
Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int J Biol Sci (2014) 1.07
Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist (2014) 1.05
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol (2011) 1.05
Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging (2007) 1.01
Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice. Can Urol Assoc J (2013) 1.01
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert Opin Ther Targets (2005) 1.01
Pain flare in patients with bone metastases after palliative radiotherapy--a nested randomized control trial. Support Care Cancer (2006) 1.01
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs (2007) 1.01
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer (2007) 1.00
Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther (2010) 1.00
Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res (2013) 1.00
Chemotherapy for prostate cancer: Clinical practice in Canada. Can Urol Assoc J (2013) 0.99
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer (2002) 0.98
The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol (2013) 0.97
Suramin's development: what did we learn? Invest New Drugs (2002) 0.97
PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Semin Nucl Med (2011) 0.95
Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients. Int J Clin Oncol (2005) 0.94
Current treatment strategies for castration-resistant prostate cancer. Korean J Urol (2011) 0.93
Prostate cancer: 11. Alternative approaches and the future of treatment. CMAJ (1999) 0.93
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br J Cancer (2004) 0.93
Management of high-risk localized prostate cancer. Adv Urol (2011) 0.93
Prostate cancer management: 2. An update on locally advanced and metastatic disease. Postgrad Med J (2003) 0.92
Overcoming docetaxel resistance in prostate cancer: a perspective review. Ther Adv Med Oncol (2012) 0.91
Targeting the glucocorticoid receptor in breast and prostate cancers. Sci Transl Med (2015) 0.91
Median-Based Incremental Cost-Effectiveness Ratio (ICER). J Stat Theory Pract (2012) 0.90
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer. Curr Treat Options Oncol (2012) 0.89
Is there a role for chemotherapy in prostate cancer? Br J Cancer (2004) 0.89
Chemotherapy for androgen-independent prostate cancer. World J Urol (2005) 0.89
Chemotherapy and its evolving role in the management of advanced prostate cancer. Asian J Androl (2014) 0.88
The role of stress proteins in prostate cancer. Curr Genomics (2007) 0.88
Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? Br J Cancer (2006) 0.88
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. Ann Oncol (2014) 0.88
On the probability of cost-effectiveness using data from randomized clinical trials. BMC Med Res Methodol (2001) 0.88
Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression? Cancer Ther (2007) 0.87
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs (2010) 0.87
Management of docetaxel failures in metastatic castrate-resistant prostate cancer. Urol Clin North Am (2012) 0.87
Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl (2011) 0.87
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl (2014) 0.86
Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Adv Urol (2012) 0.86
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur J Nucl Med Mol Imaging (2006) 0.86
Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events. Urol Oncol (2011) 0.85
Novel options for the treatment of castration-resistant prostate cancer. World J Urol (2011) 0.85
Castration-resistant prostate cancer: systemic therapy in 2012. Clinics (Sao Paulo) (2012) 0.84
Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities? Int J Biol Sci (2014) 0.84
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. Br J Cancer (2007) 0.84
The epothilones: new therapeutic agents for castration-resistant prostate cancer. Oncologist (2011) 0.84
Contemporary quality of life issues affecting gynecologic cancer survivors. Hematol Oncol Clin North Am (2011) 0.84
Glucocorticoids and prostate cancer treatment: friend or foe? Asian J Androl (2014) 0.83
Emerging therapies in castrate-resistant prostate cancer. Curr Urol Rep (2010) 0.83
Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients. J Cancer Res Clin Oncol (2011) 0.83
Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer. Br J Cancer (2004) 0.83
Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. Oncologist (2014) 0.83
The project data sphere initiative: accelerating cancer research by sharing data. Oncologist (2015) 0.83
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2015) 0.83
Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea. Cancer Res Treat (2010) 0.82
Targeted α-particle therapy of bone metastases in prostate cancer. Clin Nucl Med (2013) 0.82
A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life. World J Urol (2003) 0.82
A phase II trial of irinotecan in hormone-refractory prostate cancer. Invest New Drugs (1999) 0.82
Surrogate end points of quality of life assessment: have we really found what we are looking for? Health Qual Life Outcomes (2003) 0.81
Biomarker development in the context of urologic cancers. Urol Oncol (2015) 0.81
Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Clin Med Insights Oncol (2011) 0.81
ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Investig Drugs (2008) 0.81
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med (2000) 18.12
Current concepts of the immunological function of the thymus. Physiol Rev (1967) 8.37
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol (2000) 8.08
Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med (1997) 7.61
The spliceosome deposits multiple proteins 20-24 nucleotides upstream of mRNA exon-exon junctions. EMBO J (2000) 7.54
The DNA sequence and comparative analysis of human chromosome 20. Nature (2002) 7.40
The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay. EMBO J (2001) 5.69
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer (2000) 4.96
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol (1996) 4.07
Pre-mRNA splicing alters mRNP composition: evidence for stable association of proteins at exon-exon junctions. Genes Dev (2000) 3.74
Adjuvant systemic therapy and survival after breast cancer. N Engl J Med (1994) 3.35
Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. J Exp Med (1990) 3.01
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol (1999) 2.97
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med (1998) 2.85
Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res (2000) 2.65
Branch nucleophile selection in pre-mRNA splicing: evidence for the bulged duplex model. Genes Dev (1994) 2.63
Structural brain abnormalities associated with deletion at chromosome 22q11: quantitative neuroimaging study of adults with velo-cardio-facial syndrome. Br J Psychiatry (2001) 2.49
Kaposi's sarcoma in recipients of renal transplants. Am J Med (1979) 2.45
Eye contact and face scanning in early infancy. Science (1977) 2.20
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol (1999) 2.03
Polydactyly and psychosis. Five cases of co-occurrence. Br J Psychiatry (1998) 2.02
Structure of the detoxification catalyst mercuric ion reductase from Bacillus sp. strain RC607. Nature (1991) 2.01
Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer (1997) 1.85
The human Prp8 protein is a component of both U2- and U12-dependent spliceosomes. RNA (1999) 1.81
The effects of thymus and other lymphoid organs enclosed in millipore diffusion chambers on neonatally thymectomized mice. J Exp Med (1965) 1.78
Precursor RNAs harboring nonsense codons accumulate near the site of transcription. Mol Cell (2001) 1.72
Bimolecular exon ligation by the human spliceosome. Science (1997) 1.72
The C-terminal region of hPrp8 interacts with the conserved GU dinucleotide at the 5' splice site. RNA (1999) 1.71
Expanded CAG repeats in schizophrenia and bipolar disorder. Nat Genet (1995) 1.66
Evidence-based medicine: useful tools for decision making. Med J Aust (2001) 1.65
Use of a site-directed triple mutant to trap intermediates: demonstration that the flavin C(4a)-thiol adduct and reduced flavin are kinetically competent intermediates in mercuric ion reductase. Biochemistry (1990) 1.63
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res (1996) 1.58
Deadly diving? Physiological and behavioural management of decompression stress in diving mammals. Proc Biol Sci (2011) 1.57
Aggressive behaviour in patients with schizophrenia is associated with catechol-O-methyltransferase genotype. Br J Psychiatry (2001) 1.56
Tubulin GTP hydrolysis influences the structure, mechanical properties, and kinesin-driven transport of microtubules. J Biol Chem (1994) 1.56
Restriction of the capacity to respond to two antigens by single precursors of antibody-producing cells in culture. J Exp Med (1969) 1.55
Some physical and radiobiological properties of immunologically reactive mouse spleen cells. J Exp Med (1970) 1.55
Quality-of-life assessment: patient compliance with questionnaire completion. J Natl Cancer Inst (1992) 1.55
Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res (1997) 1.54
Linkage of susceptibility to experimental allergic encephalomyelitis to the major histocompatibility locus in the rat. J Exp Med (1973) 1.53
Modulation of Escherichia coli RecBCD activity by the bacteriophage lambda Gam and P22 Abc functions. J Bacteriol (1988) 1.50
Intravenous diazepam in the treatment of prolonged seizure activity. N Engl J Med (1967) 1.50
Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol (2004) 1.49
Isolation and characterization of Schwanniomyces alluvius amylolytic enzymes. Appl Environ Microbiol (1982) 1.49
Hospitalised patients' views on doctors and white coats. Med J Aust (2001) 1.48
The obstacles to maximising the impact of public access defibrillation: an assessment of the dispatch mechanism for out-of-hospital cardiac arrest. Heart (2007) 1.46
Acute hypercalcemia and severe bradycardia in a patient with breast cancer. CMAJ (1993) 1.45
Exploring the etiology of content specificity: factors influencing analogic transfer and problem solving. Acad Med (1998) 1.44
Minor physical anomalies and their relationship to the aetiology of schizophrenia. Br J Psychiatry (1996) 1.44
Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Ann Oncol (2014) 1.44
Biphasic energy selection for transthoracic cardioversion of atrial fibrillation. The BEST AF Trial. Heart (2007) 1.42
The relations of early television viewing to school readiness and vocabulary of children from low-income families: the early window project. Child Dev (2001) 1.39
Intron recognition comes of AGe. Nat Struct Biol (2000) 1.38
Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med (1987) 1.38
A two-stage genome scan for schizophrenia susceptibility genes in 196 affected sibling pairs. Hum Mol Genet (1999) 1.37
The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care (1997) 1.37
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol (2003) 1.35
Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann Oncol (2005) 1.35
Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res (2001) 1.33
Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol (1987) 1.31
Biometric analyses of normal skeletal muscle. Acta Neuropathol (1971) 1.31
Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol (1996) 1.31
Patients' experiences using a computerized program with a touch-sensitive video monitor for the assessment of health-related quality of life. Qual Life Res (1998) 1.31
VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol (1985) 1.30
No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol O-methyltransferase activity. Am J Psychiatry (1996) 1.28
Chromosome 22q11 deletions, velo-cardio-facial syndrome and early-onset psychosis. Molecular genetic study. Br J Psychiatry (2003) 1.27
Canadian cancer care: organizational models. Ann Intern Med (1986) 1.25
Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol (1997) 1.25
Research on health-related quality of life: dissemination into practical applications. Qual Life Res (1994) 1.25
Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck (1999) 1.25
Transmission of the hepatitis-C virus by tissue transplantation. J Bone Joint Surg Am (1995) 1.24
Drinking and schooling. J Health Econ (1993) 1.24
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer (2006) 1.24
A systematic genomewide linkage study in 353 sib pairs with schizophrenia. Am J Hum Genet (2003) 1.24
Strychnine blocks binaural inhibition in lateral superior olivary neurons. J Neurosci (1983) 1.23
Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med (1998) 1.22
Thymic control of cellular differentiation in the immunological system. Proc Soc Exp Biol Med (1968) 1.21
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol (2005) 1.21
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res (2000) 1.20
Molecular basis of bacterial resistance to organomercurial and inorganic mercuric salts. FASEB J (1988) 1.19
Internodal length and conduction velocity of cat muscle afferent nerve fibres. J Physiol (1972) 1.19
Genotype and psychological phenotype in tuberous sclerosis. J Med Genet (2004) 1.18
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol (1998) 1.17
Evidence for a linear search in bimolecular 3' splice site AG selection. Proc Natl Acad Sci U S A (2000) 1.17
Roles of RuvC and RecG in phage lambda red-mediated recombination. J Bacteriol (1999) 1.15
Animal models of spinal cord injury for evaluation of tissue engineering treatment strategies. Biomaterials (2004) 1.13
Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder. Mol Psychiatry (1998) 1.13
Evidence for the participation of Cys558 and Cys559 at the active site of mercuric reductase. Biochemistry (1989) 1.12
Preferences for cancer treatments: an overview of methods and applications in oncology. Ann Oncol (2012) 1.12
High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol (1998) 1.12
HL-A antigens and survival in Hodgkin's disease. Lancet (1971) 1.11
Beauty is in the eye of the examiner: reaching agreement about physical signs and their value. Intern Med J (2005) 1.11
Infection-induced thrombocytopenia. Semin Thromb Hemost (1982) 1.10